HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

aTyr Pharma, Inc.

Contributing Author

Recent Articles by aTyr Pharma, Inc.

May-15
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update ATYR -9.98% GlobeNewswire
May-13
aTyr Pharma to Participate in Upcoming Investor Conferences ATYR +41.42% ATYR -25.33% GlobeNewswire
May-11
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting ATYR -44.20% ATYR GlobeNewswire
Mar-05
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update ATYR -8.68% ATYR -6.45% GlobeNewswire
Feb-20
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATYR GlobeNewswire
Feb-18
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference ATYR GlobeNewswire
Feb-03
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis ATYR GlobeNewswire
Nov-10
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference ATYR GlobeNewswire
Nov-06
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update ATYR +6.05% ATYR -5.35% GlobeNewswire
Sep-30
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 ATYR -9.28% GlobeNewswire
Sep-15
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis ATYR -83.17% GlobeNewswire
Sep-05
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATYR GlobeNewswire
Aug-07
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update ATYR GlobeNewswire
Jul-22
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis ATYR -8.23% GlobeNewswire
Jun-26
aTyr Pharma to be Added to the Russell 2000 and Russell 3000 Indexes ATYR GlobeNewswire
Jun-04
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) ATYR GlobeNewswire
May-20
aTyr Pharma to Present at Upcoming Investor Conferences ATYR GlobeNewswire
May-19
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference ATYR +5.20% GlobeNewswire
May-16
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATYR +9.00% GlobeNewswire
May-14
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis ATYR -8.46% GlobeNewswire
May-07
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update ATYR +5.70% ATYR GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)